Entera Bio Ltd. (ENTX) Q2 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to NTERRA VIAL's conference call to discuss the financial and operating results for the six-month ended June 30th, 2021. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To participate during that session, you will need to press star 1 on your telephone. I would now like to hand the conference over to Ramesh Ratan, the U.S.-based CFO of Interra. Please go ahead. Good morning and welcome to the call. Joining me on today's call are Spiros Jamas, our CEO, Arthur Santora, our CMO, and Philip Schwartz, our President of R&D. A press release announcing Interra's financial and operating reserves for the first six months ended June 30, 2021, was issued earlier today. For those of you who have not yet seen it, it's available on the investor section of our website, www.enterrabio.com. On a call this morning, we will share with you a business update and review of our financial results, which will be followed by a question and answer session. Before we begin our prepared remarks, I would like to remind you that various statements we make during the call about the company's future results of operations financial position, our interpretation of data from the recently completed Phase II clinical trials of EB613, including the biomarker data released in the first quarter of 2021, our business strategy, and plans and objectives for our future operations are considered forward-looking statements within the meaning of the federal securities law. Our forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Specifically, developments related to the COVID-19 pandemic continue to evolve and the ext...